As many as six oral cancer drugs could be selected for Medicare price negotiation in the next round, which begins in 2025 for prices going into effect in 2027, according to a new analysis by researchers at the University of Washington and the University of California San Diego.
A number of diabetes drugs may also be targeted, including Novo Nordisk's Ozempic. The price negotiated for Ozempic will also be applied to Novo's other semaglutide products, Rybelsus, an oral form for diabetes, and Wegovy, an obesity drug.
The researchers list 13 out of a possible 15 drugs that could be eligible for negotiation and identified five more that might be, but for which there is less certainty because of possible changes in Medicare spending trends.

Medicare Negotiation Round Two Will Be Dominated By Oral Cancer Drugs, Researchers Predict

More from Medicare